Biotech | November 15, 2025
Merck to acquire Cidara Therapeutics for $9.2 billion
Diversifying its portfolio to include late-phase antiviral agent
Diversifying its portfolio to include late-phase antiviral agent
The observations are procedural in nature and will be responded to within the stipulated time
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
